Coşkun DOĞAN, Nesrin KIRAL, Elif Torun PARMAKSIZ, Banu SALEPÇİ, Benan ÇAĞLAYAN, Ali FİDAN, Sevda Şener CÖMERT

Kaviter ve Kaviter Olmayan Akciğer Kanserleri Arasında Klinik, Patolojik, Metabolik ve Prognostik Farklılıklar Var mı?

Amaç: Çalışmamız kaviter primer akciğer kanserlerinin klinik, radyometabolik (PET-BT) ve sağ kalım özelliklerini araştırmak için planlanmıştır. Gereç ve Yöntem: Kliniğimizde 2014-2016 yılları arasında primer akciğer kanseri tanısı almış olguların dosyaları incelendi. Olgular kaviter ve kaviter olmayan primer akciğer kanserleri olarak iki gruba ayrıldı. Her iki grubun demografik, radyolojik, klinik, radyometabolik ve sağ kalım özellikleri kayıt edildi. Her iki grubun verileri birbirleri ile karşılaştırıldı. Bulgular: Çalışmaya yaş ortalaması 61.6±9.8 yıl olan toplam 323 olgu alındı. Olguların 36’sında kavite var iken, 287’sinde kavite yoktu. Kaviter primer akciğer kanseri oranı %11.1 bulundu. Skuamöz hücreli kanserlerde kavitasyon görülme oranı belirgin olarak fazlaydı (p =0.024). Kavitasyon olan akciğer kanserlerinin boyutu (65 mm), kavitasyon olmayanlarda (50 mm) göre daha büyüktü (p =0.001). Kaviter kanserlerde medyan genel sağ kalım 14±2.7 ay iken, kaviter olmayan kanserlerde bu süre 12±0.8 aydı (p =0.887). Bunun dışında her iki grubun yaş, cinsiyet, sigara öyküsü, kanser evresi, tedavi özellikleri, radyometabolik özellikleri benzerdi (p >0.05). Sonuç: Akciğer kanserlerinde kaviteleşme en sık skuamöz hücreli kanserlerde görülür. Kaviter akciğer kanserlerinin klinik, radyometabolik ve sağ kalım özellikleri kaviter olmayanlar ile benzerdir.

Are There Clinical, Pathological, Metabolic, and Prognostic Differences Between Cavitary and Non-Cavitary Lung Cancer?

Objective: Our study was planned to investigate the clinical, radiometabolic (PET-CT), and survival properties of primary lung cancer with cavitary. Material and Method: The files of patients diagnosed as primary lung cancer in our clinic between 2014 and 2016 were examined. The cases were divided into two groups as primary lung cancer with cavity and without cavity. Demographic, radiological, clinical, radiometabolic and survival properties of both groups were recorded. The data of both groups were compared with each other. Results: A total of 323 cases with a mean age of 61.6 ± 9.8 years were included in the study. There were 36 primary lung cancer cases with and 287 lung cancer cases without cavity. The rate of primary lung cancer with cavity was 11.1%. The rate of cavitation was significantly higher in squamous cell carcinomas (p =0.024). The size of lung cancer with cavity (65 mm) was greater than lung cancer without cavity (50 mm) Mean, maximum ? (p =0.001). Median overall survival in cavitary cancers was 14 ± 2.7 months. In non-cavitary cancers, this time was 12 ± 0.8 months (p =0.887). Otherwise, age, gender, smoking history, cancer stage, treatment characteristics, radiometabolic properties and survival were similar in both groups (p >0.05). Conclusion: The most common cavitation in lung cancers is seen in squamous cell cancers. Clinical, radiometabolic and survival characteristics of cavitary lung cancers are similar to those of noncavitary lung cancer.

PDF

___

1. Kaya A, Kaya S, Çelik G, Özdemir Ö, Alper A. Approach to patients with cavitary lung disease. T Klin J Med Sci 1997; 17: 413-8.
2. Woodring JH, Fried AM. Significance of wall thickness in solitary cavites of the lung. A followup study. Am J Roentgenol 1983; 140: 473-4.
3. Kolodziejski LS, Dyczek S, Duda K, Góralczyk J, Wysocki WM, Lobaziewicz W. Cavitated tumor as a clinical subentity in squamous cell lung cancer patients. Neoplasma 2003; 50: 66-73.
4. Zorini O. Primary carcinomatous cavities of the lung. Possible role of neoplastic cells autophagism. Dis Chest 1967; 52: 329-37.
5. Chaudhuri MR. Primary pulmonary cavitating carcinomas. Thorax 1973; 28: 354-66.
6. Good CA, Holman CB. Cavitary carcinoma of the lung: roentgenologic features in 19 cases. Dis Chest 1960; 37: 289-93.
7. Wang M, Zhao J, Pan Y et al. Do tumor cavitation and sex in resected stage I non-small-cell lung cancer correlate with prognosis? World J Surg 2009; 33: 497-504.
8. Mouroux J, Padovani B, Elkaïm D, Richelme H. Should cavitated bronchopulmonary cancers be considered a separate entity? Ann Thorac Surg 1996; 61: 530-2.
9. Pentheroudakis G, Kostadima L, Fountzilas G et al. Cavitating squamous cell lung carcinomadistinct entity or not? Analysis of radiologic, histologic, and clinical features. Lung Cancer 2004; 45: 349-55.
10. Nguyen NC, Abhishek K, Nyon S, Farghaly HR, Osman MM, Reimers HJ. Are there radiographic, metabolic, and prognostic differences between cavitary and noncavitary nonsmall cell lung carcinoma? A retrospective fluorodeoxyglucose positron emission tomography/computed tomography study. Ann Thorac Med 2016; 11: 49-54.
11. Goldstraw P, Crowley J, Chansky K et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007; 2: 706-14.
12. Chiu FTS. Cavitation in lung cancers. Aust NZ J Med 1975; 5: 523-30.
13. Goto T, Maeshima A, Oyamada Y, Kato R. Cavitary Lung Cancer Lined with Normal Bronchial Epithelium and Cancer Cells. J Cancer 2011; 2: 503-6.
14. Cutler E.C, Gross R.E. Nontuberculous abscess of the lung: Etiology, treatment and results in 90 cases. J Thorac Surg 1936; 6: 25-9.
15. Vidal E, LeVeen HH, Yarnoz M, Piccone VA. Lung abscess secondary to pulmonary infarction. Ann Thorac Surg 1971;11: 557-64.
16. Mattern J, Koomagi R, Volm M. Biological characterization of subgroups of squamous cell lung carcinoma. Clin Cancer Res 1999; 5: 1459-63.
17. Dazzi H, Hasleton PS, Thatcher N et al. Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer 1989; 59: 746-9.
18. Gasinska A, Kolodziejski L, Niemiec J, Dyczek S. Clinical significance of biological differences between cavitated and solid form of squamous cell lung cancer. Lung Cancer 2005; 49: 171-9.
19. Higashi K, Ito K, Hiramatsu Y et al. 18FFDG Uptake by primary tumor as a predictor of intratumoral lymphatic vessel invasion and lymph node involvement in non-small cell lung cancer: analysis of a multicenter study. J Nucl Med 2005; 46: 267-73.
20. Sönmezoğlu K. The use of FDG-PET scanning in lung cancer. Tüberküloz ve Toraks Dergisi 2005; 53: 94-112.
21. Coffey JP, Hill JC. 18F-fluoro-2-deoxy-D-glucose standardized uptake value in cavitating non-smallcell lung carcinoma. Nucl Med Commun 2008; 29: 1040-5.
22. Onn A, Choe DH, Herbst RS et al. Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome. Radiology 2005; 237: 342-7.